Pharmacology

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Dr. Omar Tupayachi - 5 June, 2026 0

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Dr. Juan Manuel Pérez - 4 June, 2026 0

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Dr. Juan Manuel Pérez - 3 June, 2026 0

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

Institutional News

Watch Again: Clinical Implications of Structural Heart Interventions — TAVI and MitraClip in Daily Practice

solaci - 4 June, 2026 0

The recording of the webinar “Structural Interventions: TAVI and MitraClip in Daily Practice” is now available on the SOLACI YouTube channel. The activity was...

06/03 | SOLACI Technicians & Nurses Webinar – Clinical Impact of Structural Interventions: TAVI and MitraClip in Current Practice

solaci - 2 June, 2026 0

The Latin American Society of Interventional Cardiology (SOLACI), through its Technicians and Nurses Department, invites you to participate in a new scientific webinar entitled...

Open Session | Current Endovascular Treatment of Tricuspid Regurgitation

solaci - 1 June, 2026 0

SOLACI and the Argentine College of Interventional Cardioangiologists (CACI) invite you to participate in a new Open Session of the Advanced Postgraduate Course in...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy

Abbreviated Antiaggregant Treatment in High Bleeding Risk Patients from the MASTER-DAPT (15-Month Followup)

ACC 2023 | COORDINATE-DIABETES

ACC 2023 | A DUE-Study (Phase III)

ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease

Rivaroxaban in Acute Coronary Syndrome

Monotherapy with P2Y12 in Complex Interventions: Less and Less Risky

Is Using Drug-Eluting Balloons and Single Antiplatlelet Therapy Safe for Patients at High Risk for Bleeding Who Undergo Percutaneous Coronary Intervention?

Is it Possible to Reduce DAPT Time in Diabetic Patients?